雍和植发（临时代码）(90010)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

90010 雍和植发（临时代码）

未开盘 11-04 16:00:00

0.000

+0.000

--

最高0.000	最低0.000	成交量0.00
今开0.000	昨收0.000	日振幅0.00%
总市值0.00	流通市值0.00	总股本0.00
成交额0.00	换手率--	流通股本0.00
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"90010","market":"HK","secType":"STK","nameCN":"雍和植发（临时代码）","latestPrice":0,"timestamp":1730707200000,"preClose":0,"halted":8,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","marketStatusCode":0,"change":0,"latestTime":"11-04 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1730770200000},"symbolChange":{"newSymbol":"09926","executeDate":"2020-04-14"},"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1730683800000,1730692800000],[1730696400000,1730707200000]],"volumeRatio":0,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/90010","defaultTab":"news","newsList":[{"id":"2127509492","title":"交银国际：重申康方生物(09926)“买入”评级 目标价63港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2127509492","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2127509492?lang=zh_cn&edition=full","pubTime":"2021-04-13 11:01","pubTimestamp":1618282909,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研究报告，重申康方生物“买入”评级，目标价63港元。报告中称，公司去年收入为1.24亿元人民币，主要为政府补贴和利息收入。净亏损13.2  亿元人民币，主要因为高于预期的研发支出，以及可转换可赎回优先股的公允价值损失。管理层预计，2021年下半年将就宫颈癌适应症提交新药注册。另外，旗下治疗三线经典霍奇金淋巴瘤适应症的AK105已提交新药注册，预计今年上市。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/447500.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["90010","09926","03329"],"gpt_icon":0},{"id":"2126530057","title":"康方生物－Ｂ(09926-HK)跌6.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2126530057","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2126530057?lang=zh_cn&edition=full","pubTime":"2021-04-12 15:13","pubTimestamp":1618211580,"startTime":"0","endTime":"0","summary":"康方生物-B(09926-HK)截至15:09下跌6.09%，现报50.1港元，跌3.25港元。成交198万股，涉资1.01亿元。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202104121880562382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09926","90010"],"gpt_icon":0},{"id":"2126239062","title":"康方生物-B：双抗龙头再创佳绩，biopharma进阶之路正式开启","url":"https://stock-news.laohu8.com/highlight/detail?id=2126239062","media":"格隆汇APP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2126239062?lang=zh_cn&edition=full","pubTime":"2021-04-12 09:30","pubTimestamp":1618191054,"startTime":"0","endTime":"0","summary":"PD-1单药Balstilimab的ORR为11.9%，Pembrolizumab的ORR为14.3%。02 AK112：联合抗血管机制，First-in-Class品种AK112则是全球目前唯一进入临床开发阶段的基于PD-1/VEGF的双抗产品，也是康方继AK104之后第二款全球首创并进入临床开发阶段的双抗药物。未来，康方生物的AK112上市之后，或将成为另一个极具竞争力的重磅双抗产品。康方生物与中国生物制药旗下正大天晴共同开发及商业化派安普利单抗，派安普利是中国生物制药唯一可用于开发基于PD-1抗体的单一疗法或联合疗法的新药。","market":"us","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://k.sina.cn/article_5115326071_130e5ae7700101bk55.html","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://k.sina.cn/article_5115326071_130e5ae7700101bk55.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90010","09926"],"gpt_icon":0},{"id":"2126086036","title":"格隆汇港股通5日资金流入流出排行榜 | 4月9日","url":"https://stock-news.laohu8.com/highlight/detail?id=2126086036","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2126086036?lang=zh_cn&edition=full","pubTime":"2021-04-10 05:10","pubTimestamp":1618002602,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，心动公司，微盟集团，山东墨龙，康方生物-B，海吉亚医疗港股通五日资金显著流入，五日持仓占比变动分别为，1.04%，0.51%，0.44%，0.29%，0.27%。港股通数据为T+2数据，即今日披露数据为前两个交易日数据。","market":"hk","thumbnail":"https://static.tigerbbs.com/1fc1f5e2fa377c378fa230c10e0849a2","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1fc1f5e2fa377c378fa230c10e0849a2"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/data-rss/detail?id=2332","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_gelonghui","symbols":["09926","90010"],"gpt_icon":0},{"id":"2125295237","title":"格隆汇港股通5日资金流入流出排行榜 | 4月7日","url":"https://stock-news.laohu8.com/highlight/detail?id=2125295237","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2125295237?lang=zh_cn&edition=full","pubTime":"2021-04-08 05:10","pubTimestamp":1617829802,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，信达生物，康方生物-B，比亚迪电子，珠光控股，西部水泥港股通五日资金显著流入，五日持仓占比变动分别为，0.25%，0.22%，0.19%，0.17%，0.17%。此外，佳兆业集团，金斯瑞生物科技，中国奥园，汇量科技，枫叶教育港股通五日资金显著流出，五日资金显著流出，五日持仓占比变动分别为，-1.22%，-0.42%，-0.30%，-0.29%，-0.21%。港股通数据为T+2数据，即今日披露数据为前两个交易日数据。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/data-rss/detail?id=2324","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_gelonghui","symbols":["01801","90010","09926"],"gpt_icon":0},{"id":"2125711323","title":"康方生物-B(09926.HK)：双抗龙头再创佳绩，biopharma进阶之路正式开启","url":"https://stock-news.laohu8.com/highlight/detail?id=2125711323","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2125711323?lang=zh_cn&edition=full","pubTime":"2021-04-07 08:58","pubTimestamp":1617757112,"startTime":"0","endTime":"0","summary":"2021年4月1日，中国双特异性抗体药物龙头康方生物-B发布2020年业绩报告，亮点颇多。PD-1单药Balstilimab的ORR为11.9%，Pembrolizumab的ORR为14.3%。02  AK112：联合抗血管机制，First-in-Class品种AK112则是全球目前唯一进入临床开发阶段的基于PD-1/VEGF的双抗产品，也是康方继AK104之后第二款全球首创并进入临床开发阶段的双抗药物。未来，康方生物的AK112上市之后，或将成为另一个极具竞争力的重磅双抗产品。","market":"hk","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/news/detail.html?id=507722","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_gelonghui","symbols":["09926","90010"],"gpt_icon":0},{"id":"2125582716","title":"格隆汇港股通5日资金流入流出排行榜 | 4月6日","url":"https://stock-news.laohu8.com/highlight/detail?id=2125582716","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2125582716?lang=zh_cn&edition=full","pubTime":"2021-04-07 05:10","pubTimestamp":1617743402,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，保利物业，天工国际，西部水泥，康方生物-B，金山软件港股通五日资金显著流入，五日持仓占比变动分别为，0.55%，0.44%，0.37%，0.37%，0.34%。此外，佳兆业集团，绿城服务，新东方在线，金斯瑞生物科技，中海物业港股通五日资金显著流出，五日资金显著流出，五日持仓占比变动分别为，-1.19%，-1.09%，-0.58%，-0.40%，-0.38%。港股通数据为T+2数据，即今日披露数据为前两个交易日数据。","market":"us","thumbnail":"https://static.tigerbbs.com/76824cd4c5b97eaacdaab63d96995a28","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/76824cd4c5b97eaacdaab63d96995a28"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/data-rss/detail?id=2321","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_gelonghui","symbols":["06049","90010","09926"],"gpt_icon":0},{"id":"2125757136","title":"格隆汇港股通5日资金流入流出排行榜 | 4月4日","url":"https://stock-news.laohu8.com/highlight/detail?id=2125757136","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2125757136?lang=zh_cn&edition=full","pubTime":"2021-04-05 05:10","pubTimestamp":1617570602,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，保利物业，天工国际，西部水泥，康方生物-B，金山软件港股通五日资金显著流入，五日持仓占比变动分别为，0.55%，0.44%，0.37%，0.37%，0.34%。此外，佳兆业集团，绿城服务，新东方在线，金斯瑞生物科技，中海物业港股通五日资金显著流出，五日资金显著流出，五日持仓占比变动分别为，-1.19%，-1.09%，-0.58%，-0.40%，-0.38%。港股通数据为T+2数据，即今日披露数据为前两个交易日数据。","market":"hk","thumbnail":"https://static.tigerbbs.com/1fc1f5e2fa377c378fa230c10e0849a2","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1fc1f5e2fa377c378fa230c10e0849a2"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/data-rss/detail?id=2317","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_gelonghui","symbols":["90010","06049","09926"],"gpt_icon":0},{"id":"2124375695","title":"格隆汇港股通5日资金流入流出排行榜 | 4月2日","url":"https://stock-news.laohu8.com/highlight/detail?id=2124375695","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2124375695?lang=zh_cn&edition=full","pubTime":"2021-04-03 05:10","pubTimestamp":1617397802,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，保利物业，天工国际，西部水泥，康方生物-B，金山软件港股通五日资金显著流入，五日持仓占比变动分别为，0.55%，0.44%，0.37%，0.37%，0.34%。此外，佳兆业集团，绿城服务，新东方在线，金斯瑞生物科技，中海物业港股通五日资金显著流出，五日资金显著流出，五日持仓占比变动分别为，-1.19%，-1.09%，-0.58%，-0.40%，-0.38%。　　港股通数据为T+2数据，即今日披露数据为前两个交易日数据。","market":"us","thumbnail":"https://static.tigerbbs.com/528f1b5f95c1aa85d740d858963e7e8f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/528f1b5f95c1aa85d740d858963e7e8f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2021/04/03051032273311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06049","09926","90010"],"gpt_icon":0},{"id":"2124209716","title":"康方生物提交首份上市成绩单 首创双抗新药年内提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2124209716","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2124209716?lang=zh_cn&edition=full","pubTime":"2021-04-01 13:36","pubTimestamp":1617255372,"startTime":"0","endTime":"0","summary":"3月31日晚，港股公司康方生物（9926.HK）公布了上市后的首份年度成绩单。2020年报显示，2020年全年，康方生物实现其他收入净额约为1.235亿元（政府补助以及利息收入等）；同期的研发投入达 ...","market":"sh","thumbnail":"https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36"],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20210401/c628262465.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20210401/c628262465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["90010","09926"],"gpt_icon":0},{"id":"2123222627","title":"康方生物(09926.HK)2020财报：创新药密集提交NDA 首创双抗新药年内提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2123222627","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2123222627?lang=zh_cn&edition=full","pubTime":"2021-03-31 20:15","pubTimestamp":1617192928,"startTime":"0","endTime":"0","summary":"3月31日晚间，康方生物公布了截至2020年12月31日止的年度业绩。目前，Cadonilimab治疗复发或转移性宫颈癌已经被NMPA纳入突破性治疗药物名单，也被FDA授予孤儿药认定以及快速审批通道资格。此外，康方生物表示，预期将在2021年提交3项新药上市申请，包括Cadonilimab治疗复发或转移性宫颈癌、派安普利三线治疗转移性鼻咽癌和派安普利联合化疗一线治疗鳞状非小细胞肺癌。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/news/detail.html?id=506036","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_gelonghui","symbols":["159992","90010","09926","90014","06978"],"gpt_icon":0},{"id":"2123922423","title":"康方生物-B(09926.HK)公布年度业绩 研发投入大增149% 将进一步扩大合规生产能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2123922423","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2123922423?lang=zh_cn&edition=full","pubTime":"2021-03-31 19:56","pubTimestamp":1617191813,"startTime":"0","endTime":"0","summary":"格隆汇3月31日丨康方生物-B发布公告，截至2020年12月31日止年度，公司其他收入及收益净额达1.24亿元人民币，同比增长146%，主要是由于公司于联交所首次公开发售所得款项赚取的利息及当地政府对研发活动的补助增加。公司的产品管线及业务营运自上市日期起取得重大进展。截至2020年底，公司已获得12项IND批准。此外，公司预期对候选药物的生产需求将增加，公司计划进一步扩大符合美国、中国及日本、欧盟等国GMP的合规生产能力。","market":"hk","thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/news/detail.html?id=506013","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_gelonghui","symbols":["09926","90010"],"gpt_icon":0},{"id":"2123224242","title":"康方生物－Ｂ(09926.HK)全年亏损扩大至11.77亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2123224242","media":"AAFN","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2123224242?lang=zh_cn&edition=full","pubTime":"2021-03-31 19:37","pubTimestamp":1617190669,"startTime":"0","endTime":"0","summary":"康方生物－Ｂ  公布截至去年12月底止全年业绩，亏损扩大至11.77亿元，上年同期蚀3.35亿元；每股亏损1.65元。不派息。(gc/a)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":"https://static.tigerbbs.com/e9c35ed98221796867ee3eb028c7fe9e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e9c35ed98221796867ee3eb028c7fe9e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1088649&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["09926","CYB","UCmain","90010","CNHmain"],"gpt_icon":0},{"id":"2123222555","title":"康方生物-B(09926-HK)亏损扩大2.8倍至13.21亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2123222555","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2123222555?lang=zh_cn&edition=full","pubTime":"2021-03-31 19:13","pubTimestamp":1617189180,"startTime":"0","endTime":"0","summary":"【财华社讯】康方生物-B(09926-HK)公布2020年度业绩，年内亏损扩大至13.21亿元(人民币。下同)，同比亏损扩大了281.2%；其中涉及非现金一次性可转换可赎回优先股的公允价变动3.15亿...","market":"us","thumbnail":"https://static.tigerbbs.com/0dadac519bb6258dbafe32faf8a03d89","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0dadac519bb6258dbafe32faf8a03d89"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hk.eastmoney.com/a/202103311867376930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["90010","09926"],"gpt_icon":0},{"id":"2123722948","title":"康方生物-B(09926)年度研发开支同比增加149.23%至7.69亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2123722948","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2123722948?lang=zh_cn&edition=full","pubTime":"2021-03-31 18:46","pubTimestamp":1617187573,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物-B 发布截至2020年12月31日止年度业绩，该集团取得其他收入及收益净额人民币1.24亿元，同比增加146.13%;研发开支7.69亿元，同比增加149.23%。据悉，除了临床阶段和IND研究阶段的候选药物外，公司还在开发10种以上发现阶段的候选药物。正在进行中的注册性或关键试验总数增至9项。另外，公司于报告期后获得5项IND批准。","market":"hk","thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/440475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926","90010"],"gpt_icon":0},{"id":"2123567214","title":"速读社丨信立泰独立董事何素英任期届满辞职 康方生物PD1单抗获FDA突破性疗法资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2123567214","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2123567214?lang=zh_cn&edition=full","pubTime":"2021-03-30 18:46","pubTimestamp":1617101218,"startTime":"0","endTime":"0","summary":"信立泰独立董事何素英任期届满辞职3月30日，信立泰发布公告称，近日收到独立董事何素英提交的书面辞职报告。根据相关规定，何素英的任期即将届满，其申请辞去信立泰独立董事职务，同时一并辞去董事会审计委员会召集人、薪酬与考核委员会委员职务。康方生物PD1单抗获FDA突破性疗法资格3月30日，康方生物宣布FDA授予派安普利单抗突破性疗法资格，用于三线治疗转移性鼻咽癌。据悉，两性霉素B为多烯类抗真菌抗生素。","market":"sh","thumbnail":"https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-03-30/doc-ikknscsk4913362.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-03-30/doc-ikknscsk4913362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90010","09926","002294"],"gpt_icon":0},{"id":"2123267162","title":"【异动股】康方生物－Ｂ(09926-HK)涨6.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2123267162","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2123267162?lang=zh_cn&edition=full","pubTime":"2021-03-30 11:21","pubTimestamp":1617074514,"startTime":"0","endTime":"0","summary":"【财华社讯】康方生物－Ｂ(09926-HK)截至11:21上涨6.22%，现报50.35港元，涨2.95港元。成交200万股，涉资1.012亿元。（出处：FinetAI）","market":"us","thumbnail":"https://static.tigerbbs.com/de0bbe341ac5d74e1a8d74c9ca5de715","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/de0bbe341ac5d74e1a8d74c9ca5de715"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2021/03/30112132246983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09926","90010"],"gpt_icon":0},{"id":"2123106269","title":"港股异动 | 康方生物-B(9926.HK)涨超8% 旗下PD-1获FDA突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2123106269","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2123106269?lang=zh_cn&edition=full","pubTime":"2021-03-30 10:48","pubTimestamp":1617072504,"startTime":"0","endTime":"0","summary":"格隆汇3月30日丨 康方生物-B(9926.HK)涨超8%，报51.2港元，总市值418亿港元。康方生物今日发布公告，公司与中国生物制药(01177.HK)共同开发的PD-1单抗药物派安普利单抗(安尼可)(研发代号：AK105)三线治疗转移性鼻咽癌，获得美国食品药品监督管理局(“FDA”)授予突破性疗法认定。这是继FDA授予派安普利单抗三线治疗转移性鼻咽癌快速审批通道和孤儿药资格后，派安普利在美国取得的又一重要进展。这也是公司第二个肿瘤药物获得突破性疗法认定。中国生物制药(01177.HK)则涨约2%。","market":"hk","thumbnail":"https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/news/detail.html?id=504657","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_gelonghui","symbols":["09926","90010","01177"],"gpt_icon":0},{"id":"2123265640","title":"中生制药(01177.HK)及康方生物(09926.HK)共同开发药品获FDA授予突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2123265640","media":"AAFN","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2123265640?lang=zh_cn&edition=full","pubTime":"2021-03-30 08:33","pubTimestamp":1617064391,"startTime":"0","endTime":"0","summary":"中生制药  及康方生物  公布，双方共同研发的PD-1单抗药物派安普利单抗(安尼可)三线治疗转移性鼻咽癌，获得美国食品药品监督管理局(FDA)授予突破性疗法认定。(vi/t)~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1087524&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["01477","09926","90010","01177"],"gpt_icon":0},{"id":"2123214569","title":"康方生物PD1单抗获FDA突破性疗法资格，三线治疗转移性鼻咽癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2123214569","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2123214569?lang=zh_cn&edition=full","pubTime":"2021-03-30 07:41","pubTimestamp":1617061274,"startTime":"0","endTime":"0","summary":"康方生物PD1单抗获FDA突破性疗法资格，三线治疗转移性鼻咽癌 来源：医药魔方3月30日，康方生物宣布FDA授予派安普利单抗突破性疗法资格，用于三线治疗转移性鼻咽癌。2020年5月，康方生物向NMPA提交了派安普利单抗治疗至少经过二线系统化疗复发或难治性经典型霍奇金淋巴瘤的新药上市申请。","market":"sh","thumbnail":"https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-03-30/doc-ikknscsk4415384.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-03-30/doc-ikknscsk4415384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90010","09926"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.yonghegroup.cn/","compareEarnings":[{"period":"1week","weight":-0.0015},{"period":"1month","weight":-0.0954},{"period":"3month","weight":0.2355},{"period":"6month","weight":0.1231},{"period":"1year","weight":0.1644},{"period":"ytd","weight":0.2065}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"雍禾医疗是一家提供一站式毛发医疗服务的医疗集团，自2005年开始，我们一直专注于毛发医疗服务市场， 并构建了雍禾植发、史云逊医学健发、哈发达增发等多品牌服务体系。\n经过十多年的发展，我们目前在中国51个城市拥有52家医疗机构。利用标准、成熟的医生培养体系，如今我们已建立一支千余人的专业医疗团队， 其中包括二百余名注册医生及九百余名护士。目前我们已成为中国植发医疗及医疗养固服务市场的重要品牌。","exchange":"SEHK","name":"雍和植发（临时代码）","nameEN":"Yonghe Medical Group"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"雍和植发（临时代码）(90010)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供雍和植发（临时代码）(90010)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"雍和植发（临时代码）,90010,雍和植发（临时代码）股票,雍和植发（临时代码）股票老虎,雍和植发（临时代码）股票老虎国际,雍和植发（临时代码）行情,雍和植发（临时代码）股票行情,雍和植发（临时代码）股价,雍和植发（临时代码）股市,雍和植发（临时代码）股票价格,雍和植发（临时代码）股票交易,雍和植发（临时代码）股票购买,雍和植发（临时代码）股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"雍和植发（临时代码）(90010)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供雍和植发（临时代码）(90010)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}